Florida Cancer Specialists & Research Institute, LLC has named Wilfredo Blasini, MD as Medical Director of the Central Pathology Laboratory.
Fort Myers, Fla., May 15, 2023 – Florida Cancer Specialists & Research Institute, LLC (FCS) has named Wilfredo Blasini, MD as Medical Director of the Central Pathology Laboratory. Dr. Blasini will provide clinical leadership and oversight for the centralized laboratory which serves the practice’s nearly 100 locations statewide with a comprehensive testing menu, including advanced next-generation sequencing (NGS). Dr. Blasini joined FCS in 2012 as a hematopathologist and has served as co-director of the Pathology Laboratory since 2018.
FCS President & Managing Physician Lucio Gordan, MD said, “Dr. Blasini has been instrumental in building the fundamental infrastructure that now includes the most advanced technologies, a dedicated team of clinical experts and critical global partnerships. His leadership will ensure the continued success and direction of the lab as we continue to evolve and advance with innovations in molecular pathology testing and analysis.”
Dr. Blasini received his medical degree from the University of Puerto Rico School of Medicine in San Juan. He completed his residency in Anatomic Pathology and Clinical Pathology at the University of Miami School of Medicine, where he also was awarded a fellowship in Hematopathology. Dr. Blasini is Board-certified in Anatomic Pathology and Clinical Pathology and Hematology.
“FCS is at the forefront of delivering precision oncology in the community setting,” said FCS Chief Executive Officer Nathan H. Walcker. “Our centralized, state-of-the-art clinical laboratory, recognized as gold-standard in the industry, generates the data that enables our physicians to quickly diagnose a wide range of cancers and identify optimal treatment options for our patients, including opportunities for clinical trials based on their individual results.”
The 50,000-square-foot FCS Clinical Pathology Laboratory, based in Fort Myers, Florida, opened in 2010 and has steadily expanded its testing capabilities to keep pace with clinical advancements and the practice’s wide-ranging presence across Florida. NGS capabilities were launched at the centralized laboratory location in October 2021.
###
About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in prestigious medical schools and research institutes, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.
*Prior to approval
For More Information, Contact:
Michelle Robey, VP of Marketing
Michelle.Robey@FLCancer.com
(813) 767-9398
Jen Bradley, Director of Corporate Communications
Jennifer.Bradley@FLCancer.com
(847) 280-1740
Petosemtamab and Pembrolizumab: A Promising Pair in HNSCC Treatment
July 2nd 2024In an interview, Cesar Augusto Perez, MD, delved into the findings from a phase 2 study evaluating petosemtamab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Read More